Pipeline

Nkarta pipeline with NKX101, AML and MDS in Clinical; NKX101, HCC/mCRC/ICC in Preclinical; NKX019, B-cell malignancies in Clinical; CD70, CD70 + tumors in Discovery; NK + T, not disclosed in Discovery

i.v.: intravenous (systemic) administration; i.a.: intra-arterial (locoregional) administration

Lead Programs

NKX101

Engineered to target NKG2D ligands

  • Opportunity to treat a variety of hematologic malignancies and solid tumors
  • Targets of NKG2D are selectively over-expressed in cancer cells
  • Native NK activation and tumor killing largely driven by NKG2D receptor
  • For NKX101, expression of the activating chimeric receptor is increased 10X relative to nonengineered NK cells
  • OX40 selected based on superiority vs. other costimulatory domains
  • A Phase 1 clinical trial of NKX101 is currently enrolling patients. Please visit ClinicalTrials.gov for more information. Identifier: NCT04623944
NKX101 cell with highlights of the CAR and mbIL-15 receptors

NKX101: NKG2D activating receptor, OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15

NKX019

Engineered to target CD19

For patients with many B-cell malignancies, there remains a substantial unmet medical need today.

  • Large opportunity remains despite approved autologous CAR-T products:
    • Gr3+ cytokine release syndrome (CRS): 13-49%
    • Gr3+ neurotoxicity: 18-31%
    • Limited number of specialized sites can treat
  • Compelling commercial opportunity
    • A Phase 1 clinical trial of NKX019 is currently enrolling patients. Please visit ClinicalTrials.gov for more information. Identifier: NCT05020678
NKX019 cell with highlights of the CAR and mbIL-15 receptors
NKX019: Proprietary CD19 binder, OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15